How Has Biogen Soared 61% This Year, But Still Costs Only $1?
Biogen (NASDAQ: BIIB) is the latest biotech stock to light up investment news after a bombshell announcement. One of the company's drugs received unexpected clearance from the FDA, opening the door to monstrous profits in the near future. Shares leaped more than 60% to $407 on the news. That's a hefty price tag that might be prohibitive for some investors, but there's a simple strategy that you can use that makes Biogen affordable for anyone.
A 61% year-to-date return is spectacular, but it might surprise you to see that these gains were achieved in a matter of days.
Source Fool.com
